Siún M Walsh1, Emily C Zabor2, Michelle Stempel1, Monica Morrow1, Mary L Gemignani1. 1. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract
BACKGROUND: Black women with breast cancer have lower survival rates and higher recurrence rates in comparison with white women. This study compared treatment and survival outcomes for black and white women at a highly specialized tertiary care cancer center. METHODS: An institutional review board-approved, retrospective institutional database review was performed to identify all black women treated for invasive breast cancer between 2005 and 2010. Women with a prior history of breast cancer, stage IV cancer, or bilateral breast cancer were excluded. White women had similar exclusion criteria applied and were then matched to black women 1:1 by age and diagnosis year. Clinicopathologic and treatment variables were compared by race. Kaplan-Meier methodology was used to estimate overall survival (OS) and disease-free survival (DFS); a multivariable analysis was conducted with Cox regression models. RESULTS: The study group consisted of 1332 women (666 black). The median tumor size was larger in black women (1.6 vs 1.3 cm; P < .001). Black women had more nodal disease (41.1% vs 32%; P < .001) and had tumors that were more frequently an estrogen receptor-negative (32.9% vs 15%; P < .001), progesterone receptor-negative (47.1% vs 30.2%; P < .001), or triple-negative (TN) subtype (24% vs 8.9%; P < .001) in comparison with white women. Black women also had inferior DFS and OS; race was not an independent prognostic indicator in the multivariable analysis. CONCLUSIONS: Black women had more advanced disease and adverse prognostic indicators at diagnosis, but race was not an independent predictor of outcome. Black women were significantly more likely to have TN breast cancer. Further research is necessary to understand the differences in tumor biology associated with race.
BACKGROUND: Black women with breast cancer have lower survival rates and higher recurrence rates in comparison with white women. This study compared treatment and survival outcomes for black and white women at a highly specialized tertiary care cancer center. METHODS: An institutional review board-approved, retrospective institutional database review was performed to identify all black women treated for invasive breast cancer between 2005 and 2010. Women with a prior history of breast cancer, stage IV cancer, or bilateral breast cancer were excluded. White women had similar exclusion criteria applied and were then matched to black women 1:1 by age and diagnosis year. Clinicopathologic and treatment variables were compared by race. Kaplan-Meier methodology was used to estimate overall survival (OS) and disease-free survival (DFS); a multivariable analysis was conducted with Cox regression models. RESULTS: The study group consisted of 1332 women (666 black). The median tumor size was larger in black women (1.6 vs 1.3 cm; P < .001). Black women had more nodal disease (41.1% vs 32%; P < .001) and had tumors that were more frequently an estrogen receptor-negative (32.9% vs 15%; P < .001), progesterone receptor-negative (47.1% vs 30.2%; P < .001), or triple-negative (TN) subtype (24% vs 8.9%; P < .001) in comparison with white women. Black women also had inferior DFS and OS; race was not an independent prognostic indicator in the multivariable analysis. CONCLUSIONS: Black women had more advanced disease and adverse prognostic indicators at diagnosis, but race was not an independent predictor of outcome. Black women were significantly more likely to have TN breast cancer. Further research is necessary to understand the differences in tumor biology associated with race.
Authors: Mary Jo Lund; Marina Mosunjac; Kelly M Davis; Sheryl Gabram-Mendola; Monica Rizzo; Harvey L Bumpers; Sherita Hearn; Amelia Zelnak; Toncred Styblo; Ruth M O'Regan Journal: Cancer Date: 2011-06-30 Impact factor: 6.860
Authors: Katherine E Reeder-Hayes; John Bainbridge; Anne Marie Meyer; Keith D Amos; Bryan J Weiner; Paul A Godley; William R Carpenter Journal: Breast Cancer Res Treat Date: 2011-02-22 Impact factor: 4.872
Authors: Dawn Hershman; Russell McBride; Judith S Jacobson; Lois Lamerato; Kevin Roberts; Victor R Grann; Alfred I Neugut Journal: J Clin Oncol Date: 2005-09-20 Impact factor: 44.544
Authors: Katie M O'Brien; Stephen R Cole; Chiu-Kit Tse; Charles M Perou; Lisa A Carey; William D Foulkes; Lynn G Dressler; Joseph Geradts; Robert C Millikan Journal: Clin Cancer Res Date: 2010-12-15 Impact factor: 12.531
Authors: Yani Lu; Huiyan Ma; Kathleen E Malone; Sandra A Norman; Jane Sullivan-Halley; Brian L Strom; Polly A Marchbanks; Robert Spirtas; Ronald T Burkman; Dennis Deapen; Suzanne G Folger; Michael S Simon; Michael F Press; Jill A McDonald; Leslie Bernstein Journal: J Clin Oncol Date: 2011-07-25 Impact factor: 44.544
Authors: J L Wright; I M Reis; W Zhao; J E Panoff; C Takita; V Sujoy; C R Gomez; M Jorda; D Franceschi; J Hurley Journal: Breast Date: 2011-12-16 Impact factor: 4.380
Authors: Lisa A Newman; Scott Bunner; Kathryn Carolin; David Bouwman; Mary Ann Kosir; Michael White; Ann Schwartz Journal: Cancer Date: 2002-07-01 Impact factor: 6.860
Authors: Dawn L Hershman; Joseph M Unger; William E Barlow; Laura F Hutchins; Silvana Martino; C Kent Osborne; Robert B Livingston; Kathy S Albain Journal: J Clin Oncol Date: 2009-03-23 Impact factor: 44.544
Authors: Hua Guo; Qingqing Ding; Yun Gong; Michael Z Gilcrease; Min Zhao; Jun Zhao; Dawen Sui; Yun Wu; Hui Chen; Hui Liu; Jinxia Zhang; Erika Resetkova; Stacy L Moulder; Wei-Lien Wang; Lei Huo Journal: Breast Cancer Res Date: 2020-06-23 Impact factor: 6.466
Authors: Yumei Zhao; Guijun Xu; Xinpeng Guo; Wenjuan Ma; Yao Xu; Karl Peltzer; Vladimir P Chekhonin; Vladimir P Baklaushev; Nan Hu; Xin Wang; Zheng Liu; Chao Zhang Journal: Med Sci Monit Date: 2020-08-11